ReviewThe American journal of medicine2012
B-cell-depleting therapy in systemic lupus erythematosus.
Review in The American journal of medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts.Immunological reviews · 2026Review
- B cells maintain the homeostasis of splenic marginal zone antigen-presenting cells to promote the antiviral CD8Cellular & molecular immunology · 2026Article
- Single-cell profiling reveals inflammatory polarization of human carotid versus femoral plaque leukocytes.JCI insight · 2023Article
- Epstein-Barr virus infection as potential indicator of the occurrence and clinical presentation of systemic lupus erythematosus.Frontiers in immunology · 2023Article
- B Cells in Atherosclerosis: Mechanisms and Potential Clinical Applications.JACC. Basic to translational science · 2021Review
- SARS-CoV-2 vaccines in patients with SLE.Lupus science & medicine · 2021Article
- The Potential of Harnessing IL-2-Mediated Immunosuppression to Prevent Pathogenic B Cell Responses.Frontiers in immunology · 2021Review
- Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus.Journal of translational autoimmunity · 2021Article
- BANK1 interacts with TRAF6 and MyD88 in innate immune signaling in B cells.Cellular & molecular immunology · 2020Article
- B cell depletion in murine lupus using cytotoxic T lymphocytes in vivo: Feasibility and benefit.Cellular immunology · 2020Article
- Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.Frontiers in immunology · 2020Review
- Sources of Pathogenic Nucleic Acids in Systemic Lupus Erythematosus.Frontiers in immunology · 2019Review
- Detection of epitopes in systemic lupus erythematosus using peptide microarray.Molecular medicine reports · 2018Article
- Screening epitopes on systemic lupus erythematosus autoantigens with a peptide array.Oncotarget · 2017Article
- New Treatments for Systemic Lupus Erythematosus on the Horizon: Targeting Plasmacytoid Dendritic Cells to Inhibit Cytokine Production.Journal of clinical & cellular immunology · 2017Article
- Human effector B lymphocytes express ARID3a and secrete interferon alpha.Journal of autoimmunity · 2016Article
- B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease.Expert review of hematology · 2016Review
- Article
- Cogan's syndrome--clinical guidelines and novel therapeutic approaches.Clinical reviews in allergy & immunology · 2014Review
- Rationale for B cell targeting in SLE.Seminars in immunopathology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The emergence of a new class of agents (B-cell-depleting therapies) has opened a new era in the therapeutic approach to systemic lupus erythematosus, with belimumab being the first drug licensed for use in systemic lupus erythematosus in more than 50 years. Four agents deserve specific mention: rituximab, ocrelizumab, epratuzumab, and belimumab. Controlled trials have shown negative results for rituximab, promising results for epratuzumab, and positive results for belimumab. Despite these negative results, rituximab is the most-used agent in patients who do not respond or are intolerant to standard therapy and those with life-threatening presentations. B-cell-depleting agents should not be used in patients with mild disease and should be tailored according to individual patient characteristics, including ethnicity, organ involvement, and the immunological profile. Forthcoming studies of B-cell-directed strategies, particularly data from investigations of off-label rituximab use and postmarketing studies of belimumab, will provide new insights into the utility of these treatments in the routine management of patients with systemic lupus erythematosus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.